DePuy Synthes, a Johnson & Johnson company, is launching the CONDUIT Interbody Platform with EIT Cellular Titanium Technology which includes 3D printed titanium interbody implants for spinal fusion surgery and is designed to mimic natural bone.
In 2018 Johnson & Johnson acquired Emerging Implant Technologies (EIT), the Germany-based developer of innovative 3D printed technologies for spinal implants.
Because of the way in which these implants are fabricated using 3D printing, says DePuy Synthes, “…the CONDUIT Implants are 80% porous—bringing a differentiated cellular structure designed to mimic the properties of bone and assist with intra- and post-operative visualization. The cellular structure has a modulus of elasticity, or change in stiffness, similar to bone. All of these characteristics aim to help facilitate bone fusion.”
The family of CONDUIT Implants present the following features and benefits to surgeons:
- “Nanoscale surface roughness: in in-vitro studies, similar titanium materials with nanoscale features were shown to lead to an increase in adhesion of osteoblasts compared to conventional titanium materials
- A porosity of 80%, which closely mimics that of human cancellous bone with a porosity of 50%-90%
- EIT Cellular Titanium material with a modulus of elasticity similar to cancellous bone and
- Clear visualization of the space in and around the implant both intra- and post-operatively on X-ray, CT scan and MRI without significant interference as a result of the structure of the interbody cage.”
Nadav Tomer, worldwide president, Spine, DePuy Synthes, expanded on these key points to OTW, “The CONDUIT Interbody Platform contains five distinct systems that are composed of 3D printed cellular titanium. The 3D printed characteristics of the CONDUIT platform are designed to facilitate spinal fusion for patients who are suffering from degenerative spine disease and ultimately assist surgeons with clear visualization of the implant and surrounding neural elements both intra- and post-operatively.”
“Our goal as a spine business is to focus on the areas with the most potential to solve unmet clinical needs, and we are excited to add advanced materials to our interbody portfolio as another option for surgeons. The launch of the CONDUIT portfolio, together with our comprehensive interbody implant offerings for degenerative disc disease, helps us deliver life-enhancing spine solutions that advance the standard of care for patients everywhere.”
